Milestone Scientific Inc. in Livingston, New Jersey and Ordway Research Institute in Albany, New York have agreed to develop drug formulations for precise targeted delivery of drugs to affected body parts, organs, and cancerous tissue through Milestone’s CompuFlo injection technology. Milestone Scientific is a developer of computer-controlled drug delivery technologies and Ordway is a research and drug development organization.
Under the agreement, Milestone will provide Ordway with prototype CompuFlo instruments to assist Ordway in its continuing development of drug reformulations. The collaboration will help Ordway develop nanoparticulate and other drug reformulations suitable for dispensing through specialized CompuFlo instruments that Milestone will develop.
Drugs being developed by Ordway include those for treatment of arthritic joints, healing of wounds and destruction of tumeric and multisite cancers. Precise and targeted delivery of Ordway’s drug reformulations through Milestone’s instruments is expected to offer greater therapeutic benefits not available through systemic delivery. The collaboration may also lead to new patents being granted for reformulations of drugs in the public domain by Ordway and others.
* * *
You must be logged in to post a comment.